Skip to main content
. 2017 Nov 14;39(1):151–159. doi: 10.3892/or.2017.6097

Figure 3.

Figure 3.

Summarized data for semi-quantitative evaluation of HMGB1 and calreticulin expression before and after NAC in breast cancer and ESCC cases. *p<0.05, **p<0.001. HMGB1, high-mobility group box 1 protein; NAC, neoadjuvant chemotherapy; ESCC, esophageal squamous cell carcinoma.